LMATLeMaitre Vascular Inc

Health Care · Medical/Dental Instruments · Small

$84.45−1.03%

As of 23 Oct 2026Mkt cap $1.9B

Stage 13

AVOID

Fundamentals

56.3/75

Technical

5.0/15

Independent

61.3/90

GCAE viewstructural technical damage is a hard non-actionable condition

1M: +4.5%
3M: −14.6%
6M: −25.6%
1Y: −6.3%

Financials & valuation

Cached filing evidence · as of 2026-10-02

Valuation

P/E: 29.6xHist median 45.3x
Forward P/E: —No validated forward-estimate source
Price / FCF: 26.2x
FCF yield: 3.8%

Quality

ROIC: 14.7%
Operating margin: 23.8%
FCF margin: 29.8%
Current ratio: 12.9x

Growth

Revenue growth: +13.5%Latest FY YoY
Revenue CAGR: +12.8%
EPS CAGR: +19.2%
FCF CAGR: +25.3%

Capital

Share-count trend: +1.1%3Y annualised
Net cash: $11M-0.1x OCF

Annual trend

CAGR 2021–2025: +12.8%
Latest · 2025: $0B
YoY: +13.5%

GCAE Research

View full company research

Quality Research: REINFORCES
Acceleration Radar: FUNDAMENTAL GATE FAIL
THE ONE: NOT FLAGGED
Final / Opportunity: UNRESEARCHED · NEW RESEARCH

Key takeaway

Initial research finds double-digit organic growth, margin expansion and strong graft demand, partly offset by catheter weakness and the announced year-end retirement of the 29-year president; the evidence REINFORCES quality with medium confidence.

Unresolved question

Which timing read is better supported as new price and operating evidence arrives: production v2 or research v3?

Watch next

Artegraft and graft organic growth
Catheter recovery and recall effects
President succession and direct-sales execution

More details & evidence

Production decision

Stage 13: AVOID
Technical state: damaged
Rotation: tailwind
Evidence: fresh

Presentation freshness

Stage 11 market: 2026-10-23 · Massive
Financial cache: 2026-10-02
Quality Research: CURRENT
THE ONE: NOT FLAGGED

Authority

Company page: Presentation only
Scores: Frozen GCAE production outputs
Research: Research-only lanes; no score override
Private portfolio: Not loaded